GlobalData on MSN

JPM26: Vertex hopes to match cystic fibrosis success in pain and kidney disease

Vertex on track for “five launches in five disease areas over a five-year period” through emerging pain and renal franchises.
Seeking Alpha

Vertex Energy May Be Set For A Strong 2023 With These 3 Catalysts

Vertex saw disappointments in 2022, that may be about to change. Profitability may improve as onerous hedging rolled off for Q4. Shares could double from here to around $18 on my estimates (range: $10 ...
Nasdaq

Temasek-backed Vertex set to raise nearly $500 mln for new China-focused fund

Venture capital firm Vertex Ventures, backed by Singapore state investor Temasek, is set to raise nearly $500 million for a new fund that will invest in efforts to step up China's domestic tech ...
BioPharma Dive

AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations

AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...
Nasdaq

Singapore SPAC Vertex Technology set for local listing on Jan 21 - source

A Singapore special-purpose acquisition company (SPAC) backed by state investor Temasek's Vertex Venture Holdings has started the book building for its initial public offering (IPO) and is set to list ...
FierceBiotech

Vertex unveils fresh set of promising hep C data

Vertex (VRTX) has unveiled a fresh set of interim trial data supporting its quest to prove that telaprevir can significantly improve the cure rate of patients with hard-to-treat cases of hepatitis ...